Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 3, 2007, Pages 1059-1066

  Karanian, David A ^a,b   Karim, Sanjida L ^a   Wood, JodiAnne T ^b   Williams, John S ^b   Lin, Sonyuan ^b   Makriyannis, Alexandros ^b   Bahr, Ben A ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AM 374; ANANDAMIDE; BIOLOGICAL MARKER; CALPAIN; ENDOCANNABINOID; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; KAINIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; PALMITYLSULFONYL FLUORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN DAMAGE; BRAIN NERVE CELL; BRAIN PROTECTION; BRAIN REGION; CELL LOSS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSKELETON; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME ACTIVATION; ENZYME INHIBITION; EXCITOTOXICITY; HIPPOCAMPUS; NEUROPROTECTION; NONHUMAN; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RAT; SEIZURE; SURVIVAL;

AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; BRAIN; ENDOCANNABINOIDS; HIPPOCAMPUS; KAINIC ACID; MAP KINASE SIGNALING SYSTEM; NEUROPROTECTIVE AGENTS; PALMITATES; POLYUNSATURATED ALKAMIDES; RATS; SEIZURES;

EID: 34548098084     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.120147     Document Type: Article

References (56)

1. Bahr BA, Hoffman KB, Kessler M, Hennegriff M, Park GY, Yamamoto RS, Kawasaki BT, Vanderklish PW, Hall RA, and Lynch G (1996) Distinct distributions of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor subunits and a related 53,000 M(R) antigen (GR53) in brain tissue. Neuroscience 74:707-721.
2. Bahr BA, Bendiske J, Brown Q, Munirathinam S, Caba E, Rudin M, Urwyler S, Sauter A, and Rogers G (2002) Survival signaling and selective neuroprotection through glutamatergic transmission. Exp Neurol 174:37-47.
3. Bahr BA, Karanian DA, Makanji SS, and Makriyannis A (2006) Targeting the endocannabinoid system for treating brain disorders. Expert Opin Investig Drugs 15:351-365.
4. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, et al. (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15:300-302.
5. Bambrick LL, Yarowsky PJ, and Krueger BK (1995) Glutamate as a hippocampal neuron survival factor: an inherited defect in the trisomy 16 mouse. Proc Natl Acad Sci U S A 92:9692-9696.
6. Beltramo M, Stella N, Calignano A, Lin S, Makriyannis A, and Piomelli D (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277:1094-1097.
7. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, and Greenberg ME (1999) Cell survival promoted by the Ras-MAPK signaling pathway by transcription- dependent and -independent mechanisms. Science 286:1358-1362.
8. Clement AB, Hawkins EG, Lichtman AH, and Cravatt BF (2003) Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J Neurosci 23:3916-3923.
9. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, and Lichtman AH (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 98:9371-9376.
10. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, and Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83-87.
11. Deadwyler SA, Hampson RE, Bennett BA, Edwards TA, Mu J, Pacheco MA, Ward SJ, and Childers SR (1993) Cannabinoids modulate potassium current in cultured hippocampal neurons. Receptors Channels 1:121-134.
12. Derkinderen P, Toutant M, Kadaré G, Ledent C, Parmentier M, and Girault JA (2001) Dual role of Fyn in the regulation of FAK+-6,7 by cannabinoids in hippocampus. J Biol Chem 276:38289-38296.
13. Derkinderen P, Valjent E, Toutant M, Corvol JC, Enslen H, Ledent C, Trzaskos J, Caboche J, and Girault JA (2003) Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci 23:2371-2382.
14. Deutsch DG, Lin S, Hill WA, Morse KL, Salehani D, Arreaza G, Omeir RL, and Makriyannis A (1997) Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem Biophys Res Commun 231: 217-221.
15. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, and Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:686-691.
16. Dinh TP, Freund TF, and Piomelli D (2002) A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 121:149-158.
17. Egertová M, Cravatt BF, and Elphick MR (2003) Comparative analysis of fatty acid amide hydrolase and CB(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119:481-496.
18. Fegley D, Kathuria S, Mercier R, Li C, Goutopoulos A, Makriyannis A, and Piomelli D (2004) Anandamide transport is independent of fatty acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci U S A 101:8756-8761.
19. Galve-Roperh I, Rueda D, Gomez del Pulgar T, Velasco G, and Guzman M (2002) Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor. Mol Pharmacol 62:1385-1392.
20. 123I-Labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur J Pharmacol 307:331-338.
21. Gerdeman G and Lovinger DM (2001) CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 85:468-471.
22. Gifford AN, Bruneus M, Sonyuan L, Goutopoulos A, Makriyannis A, Volkow N, and Gatley JS (1999) Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM374). Eur J Pharmacol 383:9-14.
23. Giuffrida A, Rodriguez de Fonseca F, Nava F, Loubet-Lescoulie P, and Piomelli D (2000) Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. Eur J Pharmacol 408:161-168.
24. Gómez del Pulgar T, De Ceballos ML, Guzman M, and Velasco G (2002) Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 277:36527-36533.
25. Grundy RI (2002) The therapeutic potential of the cannabinoids in neuroprotection. Expert Opin Investig Drugs 11:1365-1374.
26. Hamm RJ, Pike BR, O'Dell DM, Lyeth BG, and Jenkins LW (1994) The rotarod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. J Neurotrauma 11:187-196.
27. Hansen HH, Schmid PC, Bittigau P, Lastres-Becker I, Berrendero F, Manzanares J, Ikonomidou C, Schmid HH, Fernandez-Ruiz JJ, and Hansen HS (2001) Anandamide, but not 2 arachidonoylglycerol, accumulates during in vivo neurodegeneration. J Neurochem 78:1415-1427.
28. Hayashi T, Umemori H, Mishina M, and Yamamoto T (1999) The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn. Nature 397: 72-76.
29. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
30. Kábová R, Liptakova S, Slamberova R, Pometlova M, and Velisek L (1999) Age-specific N-methyl-D-aspartate-induced seizures: perspectives for the West syndrome model. Epilepsia 40:1357-1369.
31. Karanian DA and Bahr BA (2006) Cannabinoid drugs and enhancement of endocannabinoid responses: strategies for a wide array of disease states. Curr Mol Med 6:677-784.
32. Karanian DA, Brown QB, Makriyannis A, and Bahr BA (2005a) Blocking cannabinoid activation of FAK and ERK1/2 compromises synaptic integrity in hippocampus. Eur J Pharmacol 508:47-56.
33. Karanian DA, Brown QB, Makriyannis A, Kosten TA, and Bahr BA (2005b) Dual modulation of endocannabinoid transport and fatty-acid amide hydrolase protects against excitotoxicity. J Neurosci 25:7813-7820.
34. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76-81.
35. Khaspekov LG, Brenz Verca MS, Frumkina LE, Hermann H, Marsicano G, and Lutz B (2004) Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. Eur J Neurosci 19:1691-1698.
36. Kim DJ and Thayer SA (2000) Activation of CB1 cannabinoid receptors inhibits neurotransmitter release from identified synaptic sites in rat hippocampal cultures. Brain Res 852:398-405.
37. Lastres-Becker I, Hansen HH, Berrendero F, De Miguel R, Perez-Rosado A, Manzanares J, Ramos JA, and Fernandez-Ruiz J (2002) Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse 44:23-35.
38. Maccarrone M, Gubellini P, Bari M, Picconi B, Battista N, Centonze D, Bernardi G, Finazzi-Agro A, and Calabresi P (2003) Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J Neurochem 85:1018-1025.
39. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutierrez SO, van der Stelt M, et al. (2003) CB1 Cannabinoid receptors and on-demand defense against excitotoxicity. Science 302:84-88.
40. McCracken E, Hunter AJ, Patel S, Graham DI, and Dewar D (1999) Calpain activation and cytoskeletal protein breakdown in the corpus callosum of head-injured patients. J Neurotrauma 16:749-761.
41. McKinney RA, Capogna M, Durr R, Gahwiler BH, and Thompson SM (1999) Miniature synaptic events maintain dendritic spines via AMPA receptor activation. Nat Neurosci 2:44-49.
42. Molina-Holgado E, Vela JM, Arevalo-Martin A, Almazan G, Molina-Holgado F, Borrell J, and Guaza C (2002) Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/ Akt signaling. J Neurosci 22:9742-9753.
43. Monory K, Massa F, Egertova M, Eder M, Blaudzun H, Westenbroek R, Kelsch W, Jacob W, Marsch R, Ekker M, et al. (2006) The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51:455-466.
44. Moore SA, Nomikos GG, Dickason-Chesterfield AK, Schober DA, Schaus JM, Ying BP, Xu YC, Phebus L, Simmons RM, Li D, et al. (2005) Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc Natl Acad Sci U S A 102:17852-17857.
45. Mu J, Zhuang SY, Kirby MT, Hampson RE, and Deadwyler SA (1999) Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture. J Pharmacol Exp Ther 291:893-902.
46. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, and Greenberg DA (1999) Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19:2987-2995.
47. Neumar RW, Meng FH, Mills AM, Xu YA, Zhang C, Welsh FA, and Siman R (2001) Calpain activity in the rat brain after transient forebrain ischemia. Exp Neurol 170:27-35.
48. Panikashvili D, Simenidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, and Shoami E (2001) An endogenous cannabinoid (2-arachidonylglycerol) is neuroprotective after brain injury. Nature 413:527-531.
49. Parmentier-Batteur S, Jin K, Mao XO, Xie L, and Greenberg DA (2002) Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci 22: 9771-9775.
50. Piomelli D, Beltramo M, Glasnapp S, Lin SY, Goutopoulos A, Xie X-Q, and Makriyannis A (1999) Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci U S A 96:5802-5807.
51. Ramírez B, Blazquez C, Gomez del Pulgar T, Guzman M, and de Ceballos M (2005) Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglia activation. J Neurosci 25:1904-1913.
52. Shen M, Piser TM, Seybold VS, and Thayer SA (1996) Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 16:4322-4334.
53. Shen M and Thayer SA (1998) The cannabinoid agonist Win55,212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons. Brain Res 783:77-84.
54. Singla S, Kreitzer AC, and Malenka RC (2007) Mechanisms for synapse specificity during striatal long-term depression. J Neurosci 27:5260-5264.
55. Wallace MJ, Blair RE, Falenski KW, Martin BR, and DeLorenzo RJ (2003) The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther 307:129-137.
56. Wallace MJ, Martin BR, and DeLorenzo RJ (2002) Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol 452:295-301.